Abstract
Recombinant factor VIIa (rFVIIa) has of April 2022 been approved by the European Medicines Agency for treatment of severe postpartum haemorrhage. The extended approval is based on one small open-label, non-blinded randomized trial of 84 women from 2015 showing reduced "second line" treatment, but also increased risk of thromboembolism. Systematic use of tranexamic acid and timely coagulation assessment with thromboelastography/rotational thromboelastometry are not applied. Danish and international societies recommend that rFVIIa is reserved as a last option in severe life-threatening cases of postpartum haemorrhage.
| Bidragets oversatte titel | Recombinant factor VIIa in postpartum haemorrhage |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V07220423 |
| Sider (fra-til) | 956-958 |
| Antal sider | 3 |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 185 |
| Udgave nummer | 10 |
| Tidlig onlinedato | 21 nov. 2022 |
| Status | Udgivet - 15 maj 2023 |
Emneord
- Factor VIIa/therapeutic use
- Female
- Humans
- Postpartum Hemorrhage/drug therapy
- Randomized Controlled Trials as Topic
- Recombinant Proteins/therapeutic use